Journal Article

Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response

Cernera, Gustavo, Formisano, Pietro, Palmieri, Giovannella, Gelzo, Monica, Scalia, Giulia, Tortora, Marianna, Giuliano, Mario, De Placido, Pietro, Ottaviano, Margaret, Pietroluongo, Erica, Raia, Maddalena, Castaldo, Giuseppe

2023

Overview

BackgroundThymic epithelial tumors (TETs) are rare malignancies with heterogeneous clinical manifestations. The high frequency of autoimmune paraneoplastic disorders observed in such patients requires caution when using COVID-19 vaccines. Furthermore, TETs are often associated with severe immunodeficiency, making it difficult to predict vaccine immunization. Therefore, we aimed to evaluate immune response to COVID-19 vaccine in patients with TETs.MethodsWe conducted a prospective study enrolling patients who underwent the SARS-Cov-2 mRNA full vaccine cycle (two doses plus a booster after 6 months of BNT162b2). All patients were enrolled before receiving 1st vaccine dose and were followed over the vaccination cycle for up to 6 months after the booster dose to i) assess humoral and cellular responses, ii) define biomarkers predictive of effective immunization, and iii) evaluate the safety of the vaccine.ResultsAt the end of the full vaccine cycle, 27 (61.4%) patients developed humoral and 38 (86.4%) cellular responses (IFN γ release by stimulated cells) and showed an increase in activated TH1 and TH17 cells, particularly significant after the booster dose. The number of B and T lymphocytes at baseline was predictive of humoral and cellular responses, respectively. Patients with no evidence of tumor lesions had a higher probability of achieving a humoral response than those with evidence of the disease. Furthermore, the percentage of patients with immune-related disorders (75%), particularly Good’s syndrome (47.7%) and myasthenia gravis (29.5%), did not change over the entire vaccine cycle. Overall, 19 of the 44 enrolled patients (43.2%) had COVID-19 during the observation period; none required hospitalization or oxygen support, and no fatalities were observed.ConclusionSARS-Cov-2 mRNA vaccine determines the immune responses in patients with TET, particularly after the booster dose, and in patients with no evidence of tumor lesions. Preliminary analysis of B and T lymphocytes may help identify patients who have a lower probability of achieving effective humoral and cellular responses and thus may need passive immunization. The vaccine prevented severe COVID-19 infection and is safe.

• Publisher: Frontiers Media SA,Frontiers Media S.A
• Subject: Antibodies / Antigens / Biomarkers / booster / COVID-19 / COVID-19 vaccines / Cytokines / Enrollments / Helper cells / humoral response / Immune response / Immune response (humoral) / Immunization (passive) / Immunodeficiency / Immunology / immunophenotype / Kinases / Lymphocytes / Lymphocytes T / Malignancy / Medical research / mRNA / mRNA vaccines / Myasthenia gravis / Neuromuscular junctions / Patients / Peptides / Proteins / Severe acute respiratory syndrome coronavirus 2 / Software / thymic epithelial tumors (TETs) / Thymus / Tumor necrosis factor-TNF / Tumors / vaccine